A new Phase 3 clinical trial has begun recruiting patients with advanced non-small cell lung cancer (NSCLC) to study the effectiveness of a novel monoclonal antibody. The antibody, known as sigvotatug vedotin, targets integrin beta-6 (IB6), a protein that is overexpressed in certain cancer cells, including those found in NSCLC. This type of lung cancer is the most common, accounting for about 87% of all lung cancer cases. NSCLC often goes undetected until it has metastasized, making it a difficult cancer to treat.
Integrins, a family of transmembrane receptors, have recently gained attention for their role in cancer progression. These proteins facilitate communication between the extracellular matrix, which regulates cell functions, and the cytoskeleton, which supports cell structure. The pathway plays a key role in gene expression. In lung cancer, high levels of IB6 are correlated with cancer cell growth, making it an attractive target for treatment.
The new Phase 3 trial, called Sigvie-003, will test sigvotatug vedotin in combination with Merck’s immunotherapy drug, Keytruda (pembrolizumab). Researchers hope that combining these two treatments will improve the efficacy of Keytruda, which is already used in many cancer treatments. The trial will compare the combination therapy to Keytruda alone in patients with advanced or metastatic NSCLC.
Initial results from an earlier Phase 1 trial showed promising results. When used together with Keytruda, sigvotatug vedotin demonstrated objective response rates between 50% and 61.5% in patients with different levels of PD-L1 expression. PD-L1 is a protein found on tumor cells, and its presence can affect how the body responds to immunotherapy. The Phase 1 trial showed manageable safety profiles, with 80% of patients experiencing any-grade treatment-related adverse events and 37% experiencing grade ≥3 adverse events.
The Phase 3 Sigvie-003 trial will enroll 714 patients who are not candidates for surgery and who do not have mutations in EGFR, ALK, or ROS1 genes. Participants will also be required to have a PD-L1 tumor proportion score (TPS) of at least 50%, a key criterion for selecting candidates who are likely to benefit from immunotherapy. The primary endpoints for the study are overall survival and progression-free survival, while secondary endpoints include safety, tolerability, and response rates.
Researchers are optimistic that the combination of sigvotatug vedotin and Keytruda will offer a new treatment option for patients with advanced lung cancer, an area where few effective treatments exist. This trial represents a step forward in the fight against a disease that remains one of the leading causes of cancer-related deaths worldwide. The study is currently underway, and the results will be closely monitored by the scientific community.
Related topics:
- Pediatric Surgeon at Studer Family Children’s Hospital Discusses Growing Dangers of Products for Kids
- Saint Agatha Foundation Raises Over $2.2 Million to Support Breast Cancer Patients in Central New York
- Seren Lodge Mental Health Facility Opens in Chester, Offering Care to Women in North Wales and England
